Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRX AcelRx Pharmaceuticals		$0.77	$0.43 ▼ $2.78	$14.58M	0.52	137,683 shs	243,500 shs
CTMX CytomX Therapeutics	$2.13 -4.5%	$1.03	$0.40 ▼ $2.55	$171.72M	1.11	2.13 million shs	3.74 million shs
RENB Renovaro	$0.32 -2.1%	$0.40	$0.28 ▼ $2.34	$55.08M	0.62	1.02 million shs	1.05 million shs
SKYE Skye Bioscience	$2.20 +15.8%	$1.96	$1.14 ▼ $12.45	$68.15M	1.74	366,207 shs	267,300 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRX AcelRx Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CTMX CytomX Therapeutics	-4.48%	+3.40%	+200.00%	+212.68%	+21.71%
RENB Renovaro	-2.08%	+10.27%	-14.26%	-73.11%	-77.46%
SKYE Skye Bioscience	+15.79%	+11.68%	+20.88%	-20.86%	-81.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRX AcelRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	4.2527 of 5 stars	3.5	1.0	0.0	4.7	3.1	2.5	1.3
RENB Renovaro	0.9884 of 5 stars	0.0	2.0	0.0	0.0	2.6	3.3	0.6
SKYE Skye Bioscience	1.0648 of 5 stars	3.5	1.0	0.0	0.0	1.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRX AcelRx Pharmaceuticals	0.00	N/A	N/A	N/A
CTMX CytomX Therapeutics	3.00	Buy	$5.33	150.39% Upside
RENB Renovaro	0.00	N/A	N/A	N/A
SKYE Skye Bioscience	3.00	Buy	$16.60	654.55% Upside

Current Analyst Ratings Breakdown

Latest ACRX, RENB, CTMX, and SKYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
3/21/2025	SKYE Skye Bioscience	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
3/21/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/7/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/7/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
2/28/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRX AcelRx Pharmaceuticals	$1.77M	0.00	N/A	N/A	$2.65 per share	0.00
CTMX CytomX Therapeutics	$147.56M	1.16	N/A	N/A	($0.71) per share	-3.00
RENB Renovaro	N/A	N/A	N/A	N/A	$0.52 per share	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	($0.17) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRX AcelRx Pharmaceuticals	$47.76M	-$2.23	N/A	N/A	N/A	N/A	-81.54%	-46.02%	N/A
CTMX CytomX Therapeutics	-$570K	$0.48	12.53	N/A	N/A	10.96%	-41.47%	8.11%	8/14/2025 (Estimated)
RENB Renovaro	-$80.65M	-$0.77	N/A	∞	N/A	N/A	-61.84%	-48.07%	N/A
SKYE Skye Bioscience	-$37.65M	-$0.82	N/A	N/A	N/A	N/A	-45.78%	-37.44%	N/A

Latest ACRX, RENB, CTMX, and SKYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
3/20/2025	Q4 2024	SKYE Skye Bioscience	-$0.30	-$0.24	+$0.06	-$0.24	N/A	N/A
3/6/2025	Q4 2024	CTMX CytomX Therapeutics	-$0.23	$0.22	+$0.45	$0.22	$13.53 million	$38.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRX AcelRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRX AcelRx Pharmaceuticals	N/A	4.04	4.04
CTMX CytomX Therapeutics	N/A	1.04	1.04
RENB Renovaro	N/A	0.06	0.08
SKYE Skye Bioscience	N/A	14.19	14.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRX AcelRx Pharmaceuticals	19.79%
CTMX CytomX Therapeutics	67.77%
RENB Renovaro	71.41%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
ACRX AcelRx Pharmaceuticals	3.00%
CTMX CytomX Therapeutics	7.00%
RENB Renovaro	21.72%
SKYE Skye Bioscience	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRX AcelRx Pharmaceuticals	19	16.95 million	16.44 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
RENB Renovaro	20	172.12 million	124.24 million	Optionable
SKYE Skye Bioscience	11	30.98 million	29.43 million	Optionable

ACRX, RENB, CTMX, and SKYE Headlines

Recent News About These Companies

Leo Miller: Page 6

May 25 at 9:23 AM | entrepreneur.com

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

May 23, 2025 | zacks.com

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025 | globenewswire.com

Skye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity Treatment

May 21, 2025 | nasdaq.com

Q&A: Next wave of obesity drugs may ‘afford a lot of advantages’

May 20, 2025 | healio.com

Arecor shares climb 18% on collaboration with Skye Bioscience

May 19, 2025 | lse.co.uk

Arecor establishes partnership with Skye Bioscience to develop enhanced formulation of obesity candidate Nimacimab

May 19, 2025 | cambridgenetwork.co.uk

Skye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025 | finanznachrichten.de

Arecor enters formulation partnership with Skye Bioscience

May 19, 2025 | sharecast.com

Arecor shares jump 10% on obesity drug partnership with Skye Bioscience

May 19, 2025 | proactiveinvestors.co.uk

Arecor partners with Skye Bioscience to improve formulation of obesity drug

May 19, 2025 | proactiveinvestors.co.uk

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025 | globenewswire.com

Ensign Peak Advisors Inc Sells 132,713 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE)

May 18, 2025 | marketbeat.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of "Buy" from Analysts

May 16, 2025 | marketbeat.com

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025 | globenewswire.com

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 13, 2025 | globenewswire.com

Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...

May 12, 2025 | medpagetoday.com

Skye Bioscience (NASDAQ:SKYE) Issues Quarterly Earnings Results

May 12, 2025 | marketbeat.com

Earnings call transcript: Skye Bioscience Reports Q1 2025 Financials Amid R&D Expansion

May 10, 2025 | investing.com

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRX, RENB, CTMX, and SKYE Company Descriptions

AcelRx Pharmaceuticals NASDAQ:ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

CytomX Therapeutics NASDAQ:CTMX

$2.13 -0.10 (-4.48%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$2.13 +0.00 (+0.23%)

As of 05/27/2025 07:55 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Renovaro NASDAQ:RENB

$0.32 -0.01 (-2.08%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$0.32 +0.01 (+1.56%)

As of 05/27/2025 07:57 PM Eastern

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Skye Bioscience NASDAQ:SKYE

$2.20 +0.30 (+15.79%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$2.16 -0.04 (-1.82%)

As of 05/27/2025 07:49 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time